Develop a holistic GLP-1 strategy

An evidence-based approach to GLP-1 drugs helps you implement custom strategies that promote clinically appropriate use and consider affordability, long-term value and member health outcomes.

85%

Eighty-five percent of people who newly started glucagon-like peptide-1 (GLP-1) agonist drugs for weight loss were no longer taking the drug after two years.

The evolution of GLP-1s

When we look at historical utilization and spend patterns, we forecast that increasing GLP-1 use for weight loss by just 1% of an insured population would drive more than an additional $10 in costs PMPM, totaling 5% of a self-insured employer’s drug spend. So it’s clear that having a strong GLP-1 strategy is an essential element of a successful pharmacy benefits program. 

Year-2 cost of care $4,200 higher

Individuals without diabetes who started glucagon-like peptide-1 (GLP-1) agonist drugs for obesity experienced an average of $4,206 higher cost of care in their second year compared to similar members who did not take a GLP-1 drug for obesity. The study also shows that, across the obesity-related outcomes included in the study, no reduction in medical events was observed over the first two years of therapy.

Tap into the research

Real-world analysis of GLP-1 drugs

Demand for GLP-1 drugs for weight loss continues to increase, and data shows low adherence and increased cost in the first year.

Dive deeper

Industry-leading research on GLP-1s

Prime’s real-world, integrated data revealed further insights at Year 2, including that just 1 in 7 people remain on GLP-1 drugs for weight loss.

See more findings

Pharmacy Friends

Pharmacy Friends is a podcast dedicated to bringing industry experts to the same table to talk about what is happening in pharmacy today, what is coming in the future and, most importantly, what it means to you. Listen to our episodes that focus on the hot topic of GLP-1s and chronic weight management.

Holistic solutions for weight management

More than 73.1% of adults in the United States are either overweight or obese. In addition to the health impact, obesity costs the health care system almost $173B per year. Prime’s clinical insights report outlines where we are today and how things are shaping up for the future, demystifying trends like GLP-1s and supporting a whole-person approach to sustainable weight management.

Next-level cardiometabolic support

Conditions like obesity, diabetes, hypertension and high cholesterol can compound if left unchecked, causing serious and costly health problems. KeepWell™ offers a personalized and effective path to wellness for your members, driving better outcomes across the cardiometabolic spectrum. 
Login Portals
Compliance / Legal
Careers
© 2024 Prime Therapeutics LLC